GlassScriptPhysician profile
Prabir K Mullick
NPI 1285603126
$11,628.60
in general payments reported to CMS, 2019-2025
22 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $1,449 · 2021: $1,585 · 2022: $1,627 · 2023: $1,467 · 2024: $1,494 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,715.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,115.95 | 2021-2025 | |
| Alkermes, INC. | $1,775.57 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,513.14 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $940.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $895.44 | 2019-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $707.19 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $518.76 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Sunovion Pharmaceuticals INC. | $452.03 | 2019-2022 | |
| Lundbeck LLC | $450.05 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $433.88 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $405.79 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $384.81 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $367.46 | 2024-2025 | Cobenfy |
| Indivior INC. | $286.27 | 2019-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $123.40 | 2024 | Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $68.26 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $54.87 | 2023-2024 | Auvelity |
| Merck Sharp & Dohme LLC | $35.38 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $34.70 | 2019-2020 | |
| Eisai INC. | $34.67 | 2022 | |
| Neuronetics, INC. | $15.91 | 2024 | Neurostar Tms Therapy System |
| Noven Therapeutics, LLC | $14.91 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabir Mullick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.